CD274 and neoplasm: Immune checkpoint inhibitors, such as pembrolizumab, by blocking the interaction between the PD-1 receptor of T lymphocytes and its ligand PD-L1 on tumor cells, eliminate a key mechanism of immune suppression, triggering an exaggerated activation of PD-1+ T lymphocytes.